JnJ, others snag €215m IMI Ebola+ funds
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and NewLink Genetics are among the winners of the first round of funds granted by the Innovative Medicines Initiative (IMI) under a program aimed at speeding Ebola vaccines and diagnostics to battle the disease, which has infected more than 21,000 people in West Africa, killing nearly 8,500.